The first generation of GLP-1 receptor agonists have shown themselves to be blockbuster breakthroughs for the management of diabetes with significant treatment benefits for obesity, an even more prevalent disease with unmet patient needs. More than 90 additional drugs are already in development in this space seeking to become best in class or improve the patient experience for adherence. This session will examine the innovators seeking to make the biggest impact soonest for patients and how investors are prioritizing their capital in this sector.